Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series

Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were obs...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonehara, Kei, Tateishi, Kazunari, Araki, Taisuke, Komatsu, Masamichi, Akahane, Jumpei, Yamamoto, Hiroshi, Hanaoka, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647110/
https://www.ncbi.nlm.nih.gov/pubmed/34949996
http://dx.doi.org/10.1159/000519597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647110/
https://www.ncbi.nlm.nih.gov/pubmed/34949996
http://dx.doi.org/10.1159/000519597

Ejemplares similares